Scancell Hldgs Plc
Scancell Holdings plc, a clinical stage biopharmaceutical company, discovers and develops of immunotherapies for the treatment of cancer in the United Kingdom. Its product candidates include SCIB1/iSCIB1+ that is in Phase II for the treatment of melanoma; and SC134, an antibody for the treatment of small cell lung cancer. It also develops Modi-1, an active peptide immunotherapy that is in phase I… Read more
Scancell Hldgs Plc (SCLP) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of October 2025: 0.846x
Based on the latest financial reports, Scancell Hldgs Plc (SCLP) has a cash flow conversion efficiency ratio of 0.846x as of October 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX-7.08 Million) by net assets (GBX-8.37 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Scancell Hldgs Plc - Cash Flow Conversion Efficiency Trend (2009–2025)
This chart illustrates how Scancell Hldgs Plc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Scancell Hldgs Plc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Scancell Hldgs Plc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
GREAT WALL MOTOR-H-
BE:GRV
|
N/A |
|
EUROBOND
NSE:EUROBOND
|
N/A |
|
Idico Corporation JSC
VN:IDC
|
N/A |
|
CAMB3F
SA:CAMB3F
|
N/A |
|
SHINE TREND International Multimedia Technology CO., LTD.
TWO:6856
|
N/A |
|
BLAU3F
SA:BLAU3F
|
N/A |
|
Egyptian International Pharmaceuticals (EIPICO)
EGX:PHAR
|
N/A |
|
CPTL & COUNT PROP
BE:C20
|
N/A |
Annual Cash Flow Conversion Efficiency for Scancell Hldgs Plc (2009–2025)
The table below shows the annual cash flow conversion efficiency of Scancell Hldgs Plc from 2009 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-04-30 | GBX-3.83 Million | GBX-6.11 Million | 1.592x | -64.36% |
| 2024-04-30 | GBX-3.50 Million | GBX-15.66 Million | 4.468x | +242.12% |
| 2023-04-30 | GBX-6.23 Million | GBX-8.14 Million | 1.306x | +426.11% |
| 2022-04-30 | GBX19.48 Million | GBX-7.80 Million | -0.400x | +60.75% |
| 2021-04-30 | GBX7.65 Million | GBX-7.80 Million | -1.020x | -35.45% |
| 2020-04-30 | GBX9.34 Million | GBX-7.03 Million | -0.753x | -0.21% |
| 2019-04-30 | GBX9.34 Million | GBX-7.02 Million | -0.752x | -157.92% |
| 2018-04-30 | GBX13.94 Million | GBX-4.06 Million | -0.291x | +50.77% |
| 2017-04-30 | GBX6.50 Million | GBX-3.85 Million | -0.592x | -153.79% |
| 2016-04-30 | GBX9.99 Million | GBX-2.33 Million | -0.233x | +40.30% |
| 2015-04-30 | GBX6.75 Million | GBX-2.64 Million | -0.391x | -69.41% |
| 2014-04-30 | GBX9.08 Million | GBX-2.09 Million | -0.231x | +41.23% |
| 2013-04-30 | GBX5.09 Million | GBX-2.00 Million | -0.392x | -418.26% |
| 2012-04-30 | GBX6.97 Million | GBX859.62K | 0.123x | +132.17% |
| 2011-04-30 | GBX4.64 Million | GBX-1.78 Million | -0.383x | -76.43% |
| 2010-04-30 | GBX6.05 Million | GBX-1.31 Million | -0.217x | -7.79% |
| 2009-04-30 | GBX5.25 Million | GBX-1.06 Million | -0.202x | -- |